Affimed NV (NASDAQ:AFMD)
| 5.18 BATS BZX Real-Time Price As of 2:38pm ET |  +0.25 / +5.07%Today’s Change | 1.42 Today|||52-Week Range 5.18 | +89.05% Year-to-Date |
Latest AFMD News | Press Releases
| Affimed N.V. (AFMD) Q3 2020 Earnings Call Transcript Nov 10 / MotleyFool.com - Paid Partner Content | Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates Nov 10 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 4.93 |
| Today’s open | 4.98 |
| Day’s range | 4.86 - 5.18 |
| Volume | 27,672 |
| Average volume (3 months) | 1,014,022 |
| Market cap | $435.4M |
Data as of 2:38pm ET, 11/23/2020
Growth & Valuation
| Earnings growth (last year) | -48.51% |
| Earnings growth (this year) | +39.70% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -14.50% |
| P/E ratio | NM |
| Price/Sales | 7.35 |
| Price/Book | 8.66 |
Competitors
| ---- | ||
| ORTXOrchard Therapeutics... | -0.05 | -1.11% |
| PBYIPuma Biotechnology I... | +0.41 | +3.67% |
| CRNXCrinetics Pharmaceut... | -0.60 | -4.38% |
Data as of 2:47pm ET, 11/23/2020
Financials
| Next reporting date | March 31, 2021 |
| EPS forecast (this quarter) | -$0.00 |
| Annual revenue (last year) | $23.9M |
| Annual profit (last year) | -$36.2M |
| Net profit margin | -151.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Heidelberg, Baden Wuerttemberg |
Forecasts
